Hologic, Inc.

Hologic, Inc. is an American medical technology company that designs, manufactures, and sells diagnostic instruments, assays, breast imaging systems, and minimally invasive surgical products focused on women's health, generating $4.10 billion in revenue in fiscal 2025. The company occupies a peculiar position in med-tech: it is the dominant player in several reasonably narrow categories — 3D mammography gantries, molecular STI testing, endometrial ablation — yet operates in the shadow of the COVID testing windfall that briefly made it a $5.6 billion revenue company in fiscal 2021 before a sharp normalization erased nearly $1.6 billion of that top line over the following two years.

This is a story about what happens after the sugar rush. Hologic did not fritter away the COVID cash — it bought back nearly $3 billion of stock, reduced share count by over 15% since FY2021, and acquired Endomag and Gynesonics to fill out the breast surgery and fibroid treatment portfolios. But it also hit operational speed bumps in its core Breast Health imaging franchise, which saw organic revenue declines through the first half of fiscal 2025 as gantry replacement cycles lengthened and commercial execution faltered. The question that matters now is whether the recovery management described in mid-2025 — sequential improvement in Breast Health, a return to mid-single-digit organic growth guided for fiscal 2026, and an Envision platform launch on the horizon — represents durable reacceleration or a temporary reprieve in a business that has structurally slowed.

The file turns on a single judgment: whether Hologic's installed base of roughly 2,000 legacy mammography gantries and its deepening position in the breast cancer continuum — from screening through diagnosis to surgical intervention — gives it an underappreciated replacement-cycle tailwind, or whether pricing pressure, longer asset lives, and a maturing U.S. market mean the Breast Health franchise will struggle to outgrow the low single digits.